News

In the first half of 2015, the company intends to start patient enrollment in the Phase I trial, which will be the first-in-human study of its lead Lm-LLO

NovaMedica plans to begin marketing Benegast products in January 2015. Major products in the portfolio include: Benegast Reduflux, Benegast Redugas and Benegast Regulamine. Reduflux contains the proprietary compound

Both aspergillosis and mucormycosis are life-threatening fungal infections predominantly occurring in immunocompromised patients. The committee’s recommendation was based on data from the Cresemba development program, which included analyses

The company said that a small number of adult patients who metabolize Cerdelga more quickly or at an undetermined rate, will not be eligible for Cerdelga treatment. In

Lesinurad is a selective uric acid reabsorption inhibitor (SURI) that works by inhibiting the uric acid transporter URAT1 in the kidney, thereby increasing uric acid excretion resulting in

ShK-186 is being developed for a variety of autoimmune diseases and the results from this trial are scheduled to be reported later in 2015. The trial is designed

Last year, the company also secured orphan designation for investigational drug candidate to treat glioblastoma. OS2966 selectively blocks CD29 (integrin b1 subunit), a dominant molecule modulating cell interactions

Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies

KX2-391 (KX01), a dual Src/pre-tubulin inhibitor, is a small molecule drug that has excellent skin penetration when formulated as a topical ointment. The pre-tubulin activity causes hyperproliferating cells